中化新网讯 近日，中国科学院天津工业生物技术研究所在亚胺还原酶催化动态动力学拆分还原胺化合 成双手性中心N-取代氨基酰胺和氨基酯研究中取得新进展，为这类重要手性化合物的绿色高效合成提 供了新方法。 研究人员通过对亚胺还原酶酶库的筛选及蛋白质工程改造，获得了催化性能显著提升的突变体，该突变 体的催化效率较野生型酶提高了102倍。利用该工程酶，团队成功实现了抗癫痫药物布瓦西坦的克级规 模制备，并合成了一系列具有双手性中心的N-取代氨基酰胺、氨基酯及其内酰胺。通过晶体结构分析 与分子动力学模拟，研究人员揭示突变酶活性提高的机制。该研究为双手性中心氨基酸衍生物及其内酰 胺的高效、绿色不对称合成提供了新的生物催化策略，拓展了生物催化剂在动态动力学拆分还原胺化反 应中的应用范围。 据介绍，手性N-取代氨基酰胺和氨基酯是多种药物和农药的关键结构单元。该类化合物尤其是含多个 手性中心的N-取代氨基酰胺/氨基酯的高效不对称合成一直存在挑战。传统化学合成方法往往依赖苛刻 反应条件或贵金属催化剂，且难以精确控制还原胺化过程中的立体选择性。因此，开发生物合成方法具 有重要意义。 ...

Core Viewpoint - The company Aorite (605116.SH) announced a share reduction plan due to the funding needs of some partners, with a maximum reduction of 2,176,600 shares, accounting for 0.54% of the total share capital [1] Group 1: Shareholding Structure - As of the announcement date, the total number of shares of the company is 406,195,234, with Tian Tai Bo Rong and its concerted parties holding a total of 170,096,400 shares, representing 41.88% of the total share capital [1] - Tian Tai Bo Rong holds 9,907,200 shares, accounting for 2.44% of the total share capital, while Zhejiang Tong Ben holds 153,583,200 shares, representing 37.81% [1] Group 2: Fundraising and Projects - Aorite was listed on the Shanghai Stock Exchange on September 21, 2020, with a total fundraising amount of 34,317.00 million yuan, and a net amount of 28,404.13 million yuan after deducting issuance costs [2] - The funds raised are intended for projects including the technical transformation of production lines for various pharmaceutical products and the construction of a pilot experimental center [2][3] - The total investment for the projects is 46,110.00 million yuan, with specific allocations for each project detailed in the report [3] Group 3: Convertible Bonds - Aorite plans to issue convertible bonds with a total face value of 81,212.00 million yuan, raising approximately 800,471,428.30 yuan after deducting issuance costs [4] - The issuance is conducted by the lead underwriter Guotai Junan Securities Co., Ltd., and the funds have been verified and deposited into the company's fundraising supervision account [4]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a robust business trajectory and potential for future expansion [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 822 million yuan, representing a year-on-year increase of 12.50% [1][2]. - The net profit attributable to shareholders was 235 million yuan, up 24.55% year-on-year, while the net profit excluding non-recurring items reached 226 million yuan, reflecting a growth of 20.94% [1][2]. - The gross margin and net margin for H1 2025 were 60.11% and 28.58%, respectively, showing improvements of 309 basis points and 277 basis points compared to the previous year [2]. Business Segments - The raw material pharmaceutical business exhibited rapid growth, with revenue in H1 2025 reaching 700 million yuan, a year-on-year increase of 24.68% [3]. - Key product categories such as cardiovascular, respiratory, women's health, nervous system, and anti-infection raw materials showed steady growth, while new products in the peptide and oligonucleotide segments contributed to sales growth [3]. Future Outlook - The company anticipates continued growth in key products like Dydrogesterone, Abiraterone, and others, alongside new product launches expected to drive revenue increases over the next 3-5 years [2][4]. - The company is focusing on expanding hospital coverage for Dydrogesterone, with 1,754 new hospital additions in H1 2025, leading to a sales revenue of approximately 95.7 million yuan, a 3.5% increase year-on-year [2]. Investment Recommendations - The company is expected to maintain high growth rates in the coming years due to the ongoing expansion of existing products and the commercialization of potential blockbuster products [4]. - Revenue forecasts for 2025-2027 have been adjusted to 1.777 billion, 2.154 billion, and 2.591 billion yuan, respectively, with corresponding EPS estimates revised to 1.15, 1.47, and 1.84 yuan [4].